Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. announces the initiation of a groundbreaking Phase 2B clinical trial for their take-home microdosing treatment, MB22001, aimed at patients suffering from Major Depressive Disorder. The treatment, which involves self-administered sub-hallucinogenic doses of LSD, follows a successful Phase 2A trial showing significant remission in depressed patients. MindBio’s innovation represents a potential shift in treating depressive disorders, emphasizing affordability, accessibility, and minimal side effects.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
